Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | BTN3A1 | O00481 | 6/20 | 0.40 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18293558 | 1.00 | CYP3A4 (0.45) | CYP3A4CYP2C9BTN3A1TMPRSS2RIPK1 | |
| SCHEMBL10120472 | 1.00 | CYP3A4 (0.45) | CYP3A4CYP2C9BTN3A1TMPRSS2RIPK1 | |
| SCHEMBL10142564 | 0.95 | CYP3A4 (0.39) | CYP3A4CYP2C9BTN3A1TMPRSS2RIPK1 | |
| SCHEMBL15340437 | 0.95 | CYP3A4 (0.39) | CYP3A4CYP2C9BTN3A1TMPRSS2RIPK1 | |
| SCHEMBL12454848 | 0.94 | CYP3A4 (0.39) | CYP3A4CYP2C9BTN3A1TMPRSS2RIPK1 | |
| SCHEMBL15340432 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL10142570 | 0.94 | CYP3A4 (0.38) | CYP3A4CYP2C9BTN3A1 | |
| SCHEMBL10149550 | 0.94 | CYP3A4 (0.47) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| Gs-6620 SCHEMBL14845666 | 0.92 | CYP3A4 (0.41) | CYP3A4CYP2C9BTN3A1RIPK1 | |
| Gs-6620 SCHEMBL18293556 | 0.92 | CYP3A4 (0.41) | CYP3A4CYP2C9BTN3A1RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | FLAGSHIP PIONEERING INNOVATIONS VI, LLC | 2025-07-17 | — | — | US | disclosed |
| EP-2709613-B2 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2020-08-12 | — | — | EP | disclosed |
| US-10456414-B2 | Methods for treating HCV | GILEAD PHARMASSET LLC (US) | 2019-10-29 | — | — | US | disclosed |
| EP-2709613-B1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170189439-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2017-07-06 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20170042961-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC | 2017-02-16 | — | — | US | disclosed |
| US-20160354425-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| US-20160354425-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. | 2016-12-08 | — | — | US | disclosed |
| EP-2576534-B1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273005-A1 | METHODS FOR TREATING HCV | GILEAD SCIENCES, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-20130243726-A1 | METHODS FOR TREATING HCV | GILEAD PHARMASSET LLC (US) | 2013-09-19 | — | — | US | disclosed |
| US-8415308-B2 | 1′-substituted-carba-nucleoside prodrugs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-8415308-B2 | 1′-substituted-carba-nucleoside prodrugs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2011150288-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-12-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250228814-A1 | COMBINATION THERAPIES FOR THE TREATMENT OF VIRAL INFECTIONS | HAVCR2, EIF2AK2, MAVS | CYP3A4 4170/4885CYP2C9 4853/4885BTN3A1 2754/4885 |
| US-20130243726-A1 | METHODS FOR TREATING HCV | HAVCR2, DHFR, HCCS | CYP3A4 2272/4885CYP2C9 2479/4885BTN3A1 2126/4885 |
| US-20160354425-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CYP3A4 2756/4885CYP2C9 3695/4885BTN3A1 1713/4885 |
| US-20120020921-A1 | 1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT | PNP, TYMP, MTAP | CYP3A4 373/4885CYP2C9 1163/4885BTN3A1 3871/4885 |
| US-10456414-B2 | Methods for treating HCV | HAVCR2, HCCS, LIPC | CYP3A4 2756/4885CYP2C9 3695/4885BTN3A1 1713/4885 |
| US-20130273005-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CYP3A4 2756/4885CYP2C9 3695/4885BTN3A1 1713/4885 |
| US-20170189439-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CYP3A4 2756/4885CYP2C9 3695/4885BTN3A1 1713/4885 |
| US-20170042961-A1 | METHODS FOR TREATING HCV | HAVCR2, HCCS, LIPC | CYP3A4 2756/4885CYP2C9 3695/4885BTN3A1 1713/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.